Acceleron Pharma, Inc. (XLRN)
| Market Cap | 8.06B |
| Revenue (ttm) | 92.52M |
| Net Income (ttm) | -166.03M |
| Shares Out | 56.80M |
| EPS (ttm) | -2.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 4 |
| Last Price | $129.91 |
| Previous Close | $130.27 |
| Change ($) | -0.36 |
| Change (%) | -0.28% |
| Day's Open | 129.57 |
| Day's Range | 126.84 - 131.14 |
| Day's Volume | 51,727 |
| 52-Week Range | 66.44 - 144.26 |
Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.
Shares of Acceleron Pharma (NASDAQ:XLRN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 115.91% year over year to ($0.95), w...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily ther...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily thera...
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its...
Bristol-Myers Squibb Co (NYSE: BMY) and its collaborating partner Acceleron Pharma Inc (NASDAQ: XLRN) have announced that Health Canada has approved Reblozyl (luspatercept for injection) to tr...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily thera...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Acceleron's President and Chief Executive Officer, will present a corporate overview du...
These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U...
Acceleron's (XLRN) investigational therapy sotatercept receives an Orphan designation in Europe for the treatment of patients with pulmonary arterial hypertension. Shares up.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily ther...
Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?
The FDA grants orphan drug designation to Acceleron's (XLRN) ACE-1334 for the treatment of patients with systemic sclerosis.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily ther...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therap...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therap...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therape...
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2020 Results - Earnings Call Transcript
Acceleron Pharma's (XLRN) CEO Habib Dable On Q3 2020 Results - Quick Version Earnings Call Transcript
Acceleron (XLRN) delivered earnings and revenue surprises of -20.00% and -17.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily thera...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily thera...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therap...
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to ge...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its ...
Acceleron Pharma Plan For Sotatercept Adds To Buy Conviction
MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced today that Health Canada has approved REBLOZYL® (luspatercept)...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.
Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?
The Reblozyl launch by partner Bristol-Myers Squibb is going well.
It's not uncommon for stocks that have significantly outperformed for several months to take a breather.
Acceleron Pharma's (XLRN) CEO Habib Dable on Q2 2020 Results - Earnings Call Transcript
Acceleron (XLRN) posts a narrower-than-expected Q2 loss owing to increased revenues.
Acceleron (XLRN) delivered earnings and revenue surprises of 38.18% and 23.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.
New York, New York--(Newsfile Corp. - August 3, 2020) - Levi & Korsinsky announces it has commenced an investigation of Acceleron Pharma Inc.
Acceleron (XLRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acceleron (XLRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therap...
NEW YORK, July 6, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acceleron Pharma Inc. ("Acceleron...
Acceleron (XLRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
About XLRN
Acceleron Pharma, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for ... [Read more...]
| Industry Biotechnology | IPO Date Sep 19, 2013 |
| CEO Habib Dable | Employees 312 |
| Stock Exchange NASDAQ | Ticker Symbol XLRN |
Financial Performance
In 2020, XLRN's revenue was $92.52 million, an increase of 25.04% compared to the previous year's $73.99 million. Losses were -$166.03 million, 33.0% more than in 2019.
Analyst Forecasts
According to 13 analysts, the average rating for XLRN stock is "Buy." The 12-month stock price forecast is 145.42, which is an increase of 11.94% from the latest price.